SecBot SecBot
Biotech Drug Report Generated Nov 2, 2026

KB113

KRYS·Krystal Biotech, Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Pilot study (proof-of-concept, equivalent to early Phase 1/2)
Time to market
KB113 is in early-stage development with no registered Phase 2/3 trial and no defined regulatory timeline. The company is in discussions with the FDA to determine the clinical development plan. If a pivotal program is agreed upon and initiated in 2027, potential approval would likely be several years away, barring a breakthrough or accelerated pathway.
Why 3/10
KB113 has no hard dated catalyst in the next ~12 months: the pilot study data was already reported (October 15, 2026), and the company is in early FDA discussions to define the clinical development plan. No PDUFA date, pivotal readout, or AdComm is scheduled. KB113 is an early-stage program at a commercial-stage company with multiple other pipeline assets, so its impact on the stock is limited relative to VYJUVEK revenue and later-stage readouts (KB803, KB801).
Actionable Insight NEUTRAL

Watch for Krystal Biotech's announcement of FDA alignment on KB113's clinical development plan, which will define whether the program advances into a registrational trial or requires additional dose-finding studies. The small pilot (n=3) provides proof-of-concept but the regulatory path and timeline remain undefined, making KB113 a pipeline story rather than a near-term catalyst.

Price Chart

Loading chart...

Executive Summary

KB113 is an investigational intratumoral gene therapy from Krystal Biotech (KRYS) that uses a modified, non-replicating herpes simplex virus to deliver IL-2 and IL-12 directly into skin tumors. On October 15, 2026, the company reported positive proof-of-concept data from a 3-patient pilot study in Gorlin syndrome, a rare genetic condition that causes numerous basal cell carcinomas. Over 83% of assessed lesions regressed, including tumors that were never directly injected, and all adverse events were mild or moderate. The company has initiated FDA discussions to define the path to advanced clinical development, but no specific Phase 2/3 trial design, timeline, or PDUFA date has been set. KB113 is an early-stage program at a commercial-stage company whose primary value driver is the approved product VYJUVEK (dystrophic epidermolysis bullosa), which generated $127.3M in Q3 2026 revenue.

How It Works

KB113 is a modified herpes simplex virus (HSV-1) that has been engineered to be unable to replicate or cause disease. It is injected directly into skin tumors, where it delivers genes for two immune-stimulating proteins (IL-2 and IL-12). These proteins recruit and activate the patient's own immune cells to attack the injected tumor and, through a systemic effect called the abscopal effect, also attack tumors elsewhere in the body that were never injected.

Trial Status

A 3-patient, multicenter, single-arm, open-label pilot study in Gorlin syndrome patients with BCCs was completed. Results were reported on October 15, 2026, and presented at the PeDRA Annual Conference (October 15-17, 2026). The company has initiated FDA discussions for the next stage of clinical development. No Phase 2 or Phase 3 trial has been registered on ClinicalTrials.gov as of November 2, 2026.

The Two-Sided Case

▲ Bull Case5
83.1% of assessed BCC lesions (69/83) regressed across all 3 patients, including 40 of 47 non-injected lesions, demonstrating a systemic abscopal immune response that could differentiate KB113 from local therapies.
All 3 biopsied lesions with >=90% regression showed histologically confirmed complete clearance, and all 22 adverse events were mild or moderate with no serious events, suggesting a favorable safety profile.
Gorlin syndrome patients face a lifetime burden of multiple BCCs requiring repeated surgeries; a well-tolerated intratumoral immunotherapy that shrinks both injected and distant lesions could address a significant unmet need.
Krystal Biotech has a proven HSV-1 gene therapy platform (VYJUVEK is FDA-approved) and $1.2B in cash to fund KB113's development without near-term financing risk.
The company has initiated FDA discussions for advanced development, and the estimated US Gorlin syndrome prevalence could exceed 10,000 patients, representing a meaningful commercial opportunity.
▼ Bear Case5
The entire pilot study enrolled only 3 patients, far too small to establish efficacy or safety; larger trials could fail to replicate the results.
KB113 is a low-dose formulation of KB707, which itself is still in Phase 1/2 testing (OPAL-1 study); any safety or manufacturing issues with KB707 could affect KB113.
Existing oral hedgehog-pathway inhibitors (vismodegib/Erivedge, sonidegib/Odomzo) are already approved for BCC in Gorlin syndrome, though they are poorly tolerated; KB113 must demonstrate a clear tolerability and efficacy advantage to displace them.
No clinical trial is registered on ClinicalTrials.gov for KB113 in Gorlin syndrome, and the regulatory pathway (Phase 2 vs. registrational Phase 3) is undefined pending FDA discussions.
KB113 is a small, early-stage program within a company that has multiple later-stage pipeline assets (KB803, KB801, KB707, KB111) and a commercial product (VYJUVEK); its contribution to the overall stock thesis is limited in the near term.

Upcoming Catalysts

  • FDA alignment announcement on KB113's clinical development plan (timing unknown, likely months away)
  • Initiation of a Phase 2 or registrational trial for KB113 in Gorlin syndrome (no date set)
  • Interim or topline data from any future KB113 trial (no date set)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Krystal Biotech, Inc. PRESS-RELEASE KRYS ·Originating report

Sources · 8

Hover a chip for the title
1 ir.krystalbio.com2 sec.gov3 sec.gov4 pharmacally.com5 benzinga.com6 checkorphan.org7 nexi.fund8 biotechreporter.news